Eledon Pharmaceuticals
ELDN
33 hedge funds and large institutions have $46M invested in Eledon Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
3% more funds holding
Funds holding: 32 → 33 (+1)
0.81% less ownership
Funds ownership: 47.42% → 46.61% (-0.81%)
5% less capital invested
Capital invested by funds: $48.2M → $46M (-$2.18M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.23M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$449K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$308K |
| 4 |
Morgan Stanley
New York
|
+$218K |
| 5 |
BlackRock
New York
|
+$163K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZP
Zimmer Partners
New York
|
-$1.81M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$147K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$41.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.14K |
| 5 |
Renaissance Technologies
New York
|
-$2.41K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Pathstone Holdings
Englewood,
New Jersey
| $32.4K | – | – | – |
|
|
CCP
27
Clarity Capital Partners
Newport Beach,
California
| $28.6K | +$30.8K | +11,500 | New |
|
|
TSS
28
Two Sigma Securities
New York
| $27.5K | +$29.5K | +11,027 | New |
|
29
Bank of America
Charlotte,
North Carolina
| $17K | -$5 | -2 | -0% |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| $3.81K | -$41.3K | -15,426 | -91% |
|
31
JP Morgan Chase
New York
| $242 | +$16 | +6 | +7% |
|
32
Fidelity Investments
Boston,
Massachusetts
| $42 | – | – | – |
|
|
33
UBS Group
Zurich,
Switzerland
| $10 | -$147K | -54,997 | -100% |
|
ELDN Hedge Fund Activity: Q3 2024 in Review
33 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q3 2024, worth a combined $46M — down 4.5% from $48.2M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ELDN positions and 1 closed out — a net gain of 1 holder — while 10 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.23M. The largest seller was Zimmer Partners, cutting an estimated $1.81M.
- 33 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q3 2024, up from 32 in Q2 2024.
- Funds reported $46M of Eledon Pharmaceuticals stock for Q3 2024, down 4.5% quarter-over-quarter.
- 2 funds opened new Eledon Pharmaceuticals positions in Q3 2024 and 1 closed out, a net change of +1 holder.
- The largest Eledon Pharmaceuticals buyer in Q3 2024 was Vanguard Group, an estimated $1.23M added.
- The largest Eledon Pharmaceuticals seller in Q3 2024 was Zimmer Partners, an estimated $1.81M sold.
Based on aggregated 13F filings for Q3 2024.